English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/169301
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: Biological and clinical utility

AutorMisiewicz-Krzeminska, Irena; Corchete, Luis A.; Rojas, Elizabeta A.; Martínez-López, Joaquín; García-Sanz, Ramón; Oriol, Albert; Bladé, Joan; Lahuerta, Juan José; San Miguel, Jesús F. ; Mateos, Maria Victoria; Gutiérrez, Norma Carmen
Fecha de publicación2018
EditorFerrata Storti Foundation
CitaciónHaematologica 103(5): 880-889 (2018)
ResumenProtein analysis in bone marrow samples from patients with multiple myeloma has been limited by the low concentration of proteins obtained after CD138 cell selection. A novel approach based on capillary nano-immunoassay could make it possible to quantify dozens of proteins from each myeloma sample in an automated manner. Here we present a method for the accurate and robust quantification of the expression of multiple proteins extracted from CD138-purified multiple myeloma samples frozen in RLT Plus buffer, which is commonly used for nucleic acid preservation and isolation. Additionally, the biological and clinical value of this analysis for a panel of 12 proteins essential to the pathogenesis of multiple myeloma was evaluated in 63 patients with newly diagnosed multiple myeloma. The analysis of the prognostic impact of CRBN/Cereblon and IKZF1/Ikaros mRNA/protein showed that only the protein levels were able to predict progression-free survival of patients; mRNA levels were not associated with prognosis. Interestingly, high levels of Cereblon and Ikaros proteins were associated with longer progression-free survival only in patients who received immunomodulatory drugs and not in those treated with other drugs. In conclusion, the capillary nano-immunoassay platform provides a novel opportunity for automated quantification of the expression of more than 20 proteins in CD138 primary multiple myeloma samples.
Versión del editorhttps://doi.org/10.3324/haematol.2017.181628
URIhttp://hdl.handle.net/10261/169301
Identificadoresdoi: 10.3324/haematol.2017.181628
e-issn: 1592-8721
issn: 0390-6078
Aparece en las colecciones: (IBMCC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
novelnano.pdf1,25 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.